Alzheimer’s disease is diagnosed through a combination of cognitive testing, blood or spinal fluid biomarkers, brain imaging, and ruling out other treatable causes of memory loss. There is no single test that confirms it. Instead, doctors build a case by layering several types of evidence together, a process that typically unfolds over several visits spanning weeks to months.
What Happens First: The Clinical Evaluation
The process usually starts with a primary care doctor who notices cognitive concerns, either from your own report, a family member’s observations, or a routine screening. The doctor will take a detailed medical history, ask about the timeline of symptoms, review your medications, and assess whether anything in your daily functioning has changed. Medications with anticholinergic effects, alcohol use, depression, and even declining vision or hearing can all mimic or worsen cognitive symptoms, so these are addressed early.
If concerns persist, you’ll likely be referred to a specialist. Neurologists can order and interpret brain scans. Neuropsychologists conduct detailed memory and thinking tests. Geriatricians and geriatric psychiatrists evaluate cognitive changes in the context of normal aging. The National Institute on Aging recommends that people with memory problems return for follow-up every six to twelve months, since tracking changes over time is one of the most reliable ways to distinguish Alzheimer’s from normal age-related forgetfulness.
Cognitive and Memory Testing
Two widely used screening tools are the Mini-Mental State Examination (MMSE) and the Montreal Cognitive Assessment (MoCA). Both are scored out of 30 points. On the MMSE, a score of 24 or above is considered normal, and the test takes about five to ten minutes. It covers orientation (knowing where and when you are), recall, attention, calculation, and basic language tasks. The MoCA uses a cutoff of 26 and tests a broader range, including executive function, abstract reasoning, and delayed recall. It adds a point for people with fewer than 12 years of formal education to account for that difference.
These screening tools are a starting point, not a final answer. A low score flags the need for deeper evaluation, but a normal score doesn’t rule Alzheimer’s out, especially in highly educated people whose cognitive reserve can mask early decline. When screening results are borderline or unclear, a neuropsychologist may administer a more comprehensive battery of tests lasting one to three hours, evaluating specific domains like verbal learning, spatial reasoning, and processing speed in much finer detail.
Ruling Out Reversible Causes
Before settling on an Alzheimer’s diagnosis, doctors need to exclude conditions that cause similar symptoms but can be treated or reversed. The American Academy of Neurology recommends screening for three conditions in particular: depression, vitamin B12 deficiency, and hypothyroidism. All three are common in older adults and all three can cause significant memory and thinking problems that improve with treatment.
The full list of reversible causes is longer than most people expect. It includes medication side effects (especially drugs with anticholinergic activity), alcohol or drug misuse, normal pressure hydrocephalus (a buildup of fluid in the brain that causes a distinctive triad of walking difficulty, urinary incontinence, and cognitive decline), brain tumors, chronic subdural hematomas from head injuries, and infections like neurosyphilis or HIV. Standard blood work checks thyroid function, B12 levels, and basic metabolic markers. In some cases, doctors may also test for vitamin E deficiency, copper metabolism disorders, or heavy metal exposure.
A structural brain scan with CT or MRI is part of this screening. It’s not primarily looking for Alzheimer’s at this stage. It’s looking for things like tumors, evidence of strokes, fluid buildup, or bleeding that could explain the symptoms.
Brain Imaging for Alzheimer’s Specifically
Beyond ruling out other conditions, brain imaging can provide direct evidence of Alzheimer’s pathology. MRI reveals patterns of brain shrinkage that are characteristic of the disease. The hippocampus, a structure deep in the brain critical for forming new memories, is among the first regions affected. In normal aging, the hippocampus shrinks about 1% to 1.5% per year. In people with mild cognitive impairment or early Alzheimer’s, that rate accelerates to 3% to 5% per year. This shrinkage can be detected years before noticeable memory problems begin, and smaller hippocampal volume at baseline correlates strongly with worse performance on verbal learning and memory tests.
As the disease progresses, the thinning spreads outward from the entorhinal cortex (adjacent to the hippocampus) into broader regions of the brain’s surface. MRI can track this progression over time, which is one reason follow-up imaging is sometimes repeated.
PET scans offer a more specialized view. Amyloid PET scans use a radioactive tracer to detect the amyloid plaques that are a hallmark of Alzheimer’s. FDG-PET measures how actively different brain regions are using glucose, their primary fuel. In Alzheimer’s, specific areas show reduced metabolic activity in patterns that help distinguish it from other types of dementia. Tau PET scans, a newer tool, can visualize the tau tangles that are the disease’s other signature protein abnormality. These scans are more commonly used in research settings and specialized clinics than in routine primary care.
Blood and Spinal Fluid Biomarkers
This is where Alzheimer’s diagnosis has changed most dramatically in recent years. Revised diagnostic criteria now define Alzheimer’s as a biological process, not just a set of symptoms. The disease begins with molecular changes in the brain while people are still asymptomatic, and biomarkers can detect those changes directly.
The key proteins involved are amyloid beta and tau. In Alzheimer’s, amyloid beta clumps into plaques between brain cells, and tau becomes abnormally phosphorylated, forming tangles inside neurons. Cerebrospinal fluid (CSF) testing, done through a lumbar puncture, can measure levels of total tau, phosphorylated tau, and amyloid beta. The ratio of tau to amyloid beta is particularly informative: abnormally high tau or low amyloid beta in spinal fluid points toward Alzheimer’s pathology. These CSF biomarkers have been used in research and specialized clinics for years.
The bigger shift is the emergence of blood-based biomarkers, especially phosphorylated tau 217. Under the 2024 revised criteria from the National Institute on Aging and Alzheimer’s Association, these are classified as “Core 1” biomarkers. An abnormal Core 1 result is now considered sufficient to establish an Alzheimer’s diagnosis and inform clinical decisions, even before significant symptoms appear. “Core 2” biomarkers, which include tau PET scans and certain fluid markers that change later in the disease, add prognostic information and increase confidence that Alzheimer’s is actively contributing to a person’s symptoms.
This biological approach mirrors how other fields of medicine work. Oncology, for example, has long diagnosed cancers based on what’s happening at the cellular level rather than relying solely on symptoms. Alzheimer’s diagnosis is moving in the same direction.
How the Pieces Fit Together
In practice, diagnosis is layered. A typical workup begins with a clinical interview and cognitive screening, followed by blood tests and imaging to rule out treatable conditions. If Alzheimer’s remains the leading possibility, biomarker testing (blood, CSF, or PET) can confirm whether the underlying biology of the disease is present. The clinical picture, how far symptoms have progressed and how they affect daily life, is then mapped onto the biological findings using an integrated staging system.
This staging matters because Alzheimer’s pathology and symptoms don’t always line up neatly. Some people have significant amyloid buildup in the brain but function well, likely due to cognitive reserve built through education, social engagement, or other factors. Others decline faster than their biomarker profile would predict because they have additional brain pathology from vascular disease, Lewy body disease, or other conditions. The staging framework accounts for these overlaps.
The diagnostic process can feel slow, and it often requires patience. But each layer of testing serves a purpose: confirming what is there, excluding what isn’t, and building enough certainty to guide treatment decisions, including eligibility for newer therapies that target amyloid plaques directly.